Member Info for Laura2022

Blueboy

Nail

On

Head

Available

Bouncing into close at extremely oversold macd

Full ask virtually paid and limits remained

Is????

Potter

The fact you can only buy £2000-2400 says alot

Optrade

Of interest, the charts (macd and rsi) as low now as they were on the crazy move from 9p to 27p

Now NT for just £2500 at 0.5

1902

As I said, good luck and hope FAB continues to be FABulous

1902

As in all 8 days on LSE and needs to spam FAB on over 10 boards?

Troutisout1 who owns just under 3% here won't condone this

He doesnt like that type of posting

Good luck with FAB

Vik

New member on 15th July

Yeah...

Enjoy

Filtered

Gluck

Vikr

If FAB is good (which it may be) it doesnt need you spamming on 10 bulletin boards

Vikr

Can you stop spamming FAB on 10 different boards

Vikr

You've spammed FAB on about 10 different boards now

You'll have Troutisout1 telling you off

Nt for £3,000 at 0 5p

Osd

But you hopefully still think it's going to a top share of 2025 ?

Currently hard to buy

Based on the current trajectory

16th July - new contract with partner Numab

14th July - Trading statement

ahead of expectations for FY25. When compared to the year ended 30 June 2024 (FY24), these unaudited numbers would represent an increase in Total Income of approximately 46%

10th July : integration of PYC platform into global personalosed medical provoder DoseMeRx

1st July - new contract

16th June x 2 biostatistics contracts (first ones from new division)

29th May RNSPhysiomics Awarded Contract Extension

9th May RNSContract Award with New UK Client

17th Apr Physiomics Awarded New Contract

16th Apr RNS-R Publication of Peer Reviewed Article

15th Apr new contract

17th Mar RNS Contract Award with new client

Our valuation of NXP002 as a preclinical asset using a 13% WACC gives a risk adjusted valuation of NFX of £52.8m.The de-risked global value of NXP002 in IPF is £528m, which illustrates its total value potential. NFX is looking to license the asset before Phase I, in which case we would anticipate a global deal value of between $360-450m, in up front and milestone payments